0.00Open0.00Pre Close0 Volume0 Open Interest680.00Strike Price0.00Turnover0.00%IV15.68%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma130.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Martin Marietta Materials Stock Discussion
U.S. equities ended the trading day with mixed results, reflecting cautious investor sentiment amid ongoing tech stock rotation and the anticipation of potential interest rate cuts by the Federal Reserve. $Dow Jones Industrial Average (.DJI.US)$ closed at a new record high of 41,250.50, up 0.02% (or 9 points). Meanwhile, both the $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ gained 0.2%.
Key Stock M...
These names also hit fresh highs:
$Royal Caribbean (RCL.US)$ trading at levels not seen since Feb, 2021
$McCormick & Co (MKC.US)$ trading at levels not seen s...
• $Advanced Micro Devices (AMD.US)$: BMO Capital Upgrades to Outperform from Market Perform - PT $115 (from $100)
• $Amphenol (APH.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $83
• $CDW Corp (CDW.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $200 (from $205)
• $Costco (COST.US)$: Deutsche Bank Upgrades to Buy from Hold - PT $579 (from $525)
• $New Oriental (EDU.US)$ : CICC Upgrades to Outperform from M...
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet